Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

December 30, 2027

Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
DRUG

Cretostimogene Grenadenorepvec

Respective Cohort

Trial Locations (58)

10016

RECRUITING

Integrated Medical Professionals, PLLC (Solaris), New York

10461

RECRUITING

Montefiore Medical Center, The Bronx

13202

RECRUITING

SUNY Upstate, Syracuse

13210

RECRUITING

Associated Medical Professionals of NY, PLLC (US Urology Partners), Syracuse

14620

RECRUITING

University of Rochester, Rochester

17604

RECRUITING

Keystone Urology Specialists, Lancaster

19004

RECRUITING

Midlantic Urology (Solaris), Bala-Cynwyd

19104

RECRUITING

University of Pennsylvania, Philadelphia

21076

RECRUITING

Chesapeake Urology Research Associates, Hanover

23462

RECRUITING

Urology of Virginia, Virginia Beach

25304

RECRUITING

Charleston Area Medical Center, Charleston

29406

RECRUITING

Lowcountry Urology (Solaris), North Charleston

30322

RECRUITING

Emory University, Atlanta

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

32308

RECRUITING

Advanced Urogoloy Institute - Tallahassee (Solaris), Tallahassee

33771

RECRUITING

Advanced Urology Institute (Solaris), Largo

34484

RECRUITING

Advanced Urology Institute, Oxford

37209

RECRUITING

Urology Associates, PC, Nashville

38138

RECRUITING

The Conrad Pearson Clinic (Urology America), Germantown

43230

RECRUITING

Central Ohio Urology Group (US Urology Partners), Gahanna

45212

RECRUITING

The Urology Group (Solaris), Cincinnati

45267

RECRUITING

University of Cincinnati Cancer Center, Cincinnati

46032

RECRUITING

Urology of Indiana - Carmel, Carmel

46143

RECRUITING

Urology of Indiana, LLC (US Urology Partners), Greenwood

46410

RECRUITING

Urologic Specialists of Northwest Indiana (Solaris), Merrillville

47130

RECRUITING

First Urology, PSC, Jeffersonville

48084

RECRUITING

Michigan Institute of Urology (Solaris), Troy

50325

RECRUITING

Urology Center of Iowa Research, Clive

55123

RECRUITING

Minnesota Urology, Woodbury

55905

RECRUITING

Mayo Clinic Rochester, Rochester

60026

RECRUITING

Uropartners, Glenview

60415

RECRUITING

Associated Urological Specialists, Chicago Ridge

63141

RECRUITING

Specialty Clinical Research of St. Louis, St Louis

67226

RECRUITING

Wichita Urology Group, Wichita

68114

RECRUITING

Adult and Adolescent Urology, Omaha

70121

RECRUITING

Oschner Medical Center, New Orleans

70508

RECRUITING

Southern Urology (Urology America), Lafayette

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

72211

RECRUITING

Arkansas Urology, Little Rock

75231

RECRUITING

Urology Clinics of North Texas, PLLC, Dallas

76017

RECRUITING

UPNT Research Institute, LLC, Arlington

77030

RECRUITING

Houston Methodist, Houston

78229

RECRUITING

Urology San Antonio, PA dba USA Clinical Trials, San Antonio

78745

RECRUITING

Urology Austin, PLLC (Urology America), Austin

79106

RECRUITING

Amarillo Urology Research, Amarillo

80124

RECRUITING

Urology Associates, Lone Tree, Lone Tree

80228

RECRUITING

Colorado Urology, Lakewood

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

85704

RECRUITING

Arizona Urology Specialty, Tucson

90045

RECRUITING

Advanced Urology, Los Angeles

90503

RECRUITING

Genesis Research (Greater Los Angeles), Torrance

90720

RECRUITING

Genesis Research (Greater Los Angeles), Los Alamitos

92123

RECRUITING

Univeristy of Southern California, San Diego

92563

RECRUITING

Urology Center of Southern California, Murrieta

92868

RECRUITING

University of California, Irvine, Orange

93301

RECRUITING

Michael G Oefelein, MD Clinical Trials, Bakersfield

99202

RECRUITING

Spokane Urology, Spokane

229572

RECRUITING

Carolina Urologic Research Center, LLC, Myrtle Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CG Oncology, Inc.

INDUSTRY

NCT06567743 - Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Biotech Hunter | Biotech Hunter